Well, makes you wonder what the thinking is. Their total $KOD position is 22.1M shares, now valued at $2.1B, so what has compelled them to deploy $24M to buy at the top now? The company must be confident price will go higher since no follow-on offering or PIPE. We won't know if they used their ATM until their full-year report but seems like they plan on funding that way
$TXG reporting basically flat YoY growth in Q3. Guiding 5% revenue growth 2026 over 2025, yet still trading at 12X multiple
At least $TWST is guiding >20% rev growth
Nice to see another deal $RYTM! Feels like an expensive acquisition given the size of HO, but they must be confident about the potential in other MC4R-related obesity indications
$ANNX The Q4 readout is a bit convoluted. The entire 659 patient trial is split into 2 (prespecified) independent statistical sub-studies. If Vonaprument hits the primary endpoint on all 3 studies for 15 mo, they will unmask, present the data and prepare for filing...I guess in Q4?
Any communication about continuing to 24 mo alone means negative for 15 mo